Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
13
ACRS Quote, Financials, Valuation and Earnings
Last price:
$2.90
Seasonality move
:
31.13%
Day range:
$2.84 - $3.12
52-week range:
$0.86 - $5.17
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.59x
P/B ratio:
2.38x
Volume:
1.8M
Avg. volume:
4.2M
1-year change:
170.09%
Market cap:
$309.3M
Revenue:
$31.2M
EPS (TTM):
-$0.52
Analysts' Opinion
-
Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, Aclaris Therapeutics has an estimated upside of 246.02% from its current price of $2.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing -73.01% downside risk from its current price of $2.89.
Fair Value
-
According to the consensus of 5 analysts, Aclaris Therapeutics has 246.02% upside to fair value with a price target of $10.00 per share.
ACRS vs. S&P 500
-
Over the past 5 trading days, Aclaris Therapeutics has underperformed the S&P 500 by -5.94% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aclaris Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aclaris Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Aclaris Therapeutics reported revenues of $4.3M.
Earnings Growth
-
Aclaris Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aclaris Therapeutics reported earnings per share of -$0.11.
Enterprise value:
181.6M
EV / Invested capital:
1.40x
Price / LTM sales:
7.59x
EV / EBIT:
--
EV / Revenue:
6.70x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.84x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$14.5M
Return On Assets:
-19.83%
Net Income Margin (TTM):
-136.65%
Return On Equity:
-25.72%
Return On Invested Capital:
-25.72%
Operating Margin:
-222.53%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $23.5M | $21.4M | $27.1M | $9.3M | $4.3M | |
| Gross Profit | $11.9M | $8.3M | $14.5M | $1.1M | $1.9M | |
| Operating Income | -$83.9M | -$114.6M | -$62.2M | -$29.6M | -$9.7M | |
| EBITDA | -$83.1M | -$113.8M | -$61.3M | -$29.4M | -$9.5M | |
| Diluted EPS | -$1.29 | -$1.66 | -$0.52 | -$0.41 | -$0.11 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $58M | $205.8M | $256.6M | $123.1M | $132.3M | |
| Total Assets | $71.9M | $263.5M | $267.6M | $218.4M | $182.4M | |
| Current Liabilities | $12.8M | $17.8M | $19.8M | $27.3M | $18.8M | |
| Total Liabilities | $31.1M | $46.9M | $47.8M | $62M | $52.2M | |
| Total Equity | $40.8M | $216.6M | $219.8M | $156.3M | $130.2M | |
| Total Debt | $10.6M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$65.5M | -$90.7M | -$17.9M | -$24.6M | $22M | |
| Cash From Investing | $750K | $41.4M | $26.5M | $32.5M | $2.8M | |
| Cash From Financing | $72.8M | $26.7M | $5K | -$87K | $22K | |
| Free Cash Flow | -$66.2M | -$91.7M | -$18.5M | -$24.6M | $22M | |
ACRS
Sector
Market Cap
$309.3M
$43.9M
Price % of 52-Week High
55.9%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
170.09%
-29.11%
Beta (5-Year)
0.451
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.03
200-day SMA
Buy
Level
$1.58
Bollinger Bands (100)
Buy
Level
0.9 - 3
Chaikin Money Flow
Buy
Level
37.4M
20-day SMA
Sell
Level
$3.51
Relative Strength Index (RSI14)
Sell
Level
44.77
ADX Line
Buy
Level
13.46
Williams %R
Buy
Level
-86.5672
50-day SMA
Buy
Level
$2.70
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
208.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.5471)
Sell
CA Score
(Annual)
Level (-1.4233)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.7775)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Stock Forecast FAQ
In the current month, ACRS has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ACRS average analyst price target in the past 3 months is $10.00.
-
Where Will Aclaris Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aclaris Therapeutics share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Aclaris Therapeutics?
Analysts are divided on their view about Aclaris Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aclaris Therapeutics is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Aclaris Therapeutics's Price Target?
The price target for Aclaris Therapeutics over the next 1-year time period is forecast to be $10.00 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ACRS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aclaris Therapeutics is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACRS?
You can purchase shares of Aclaris Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aclaris Therapeutics shares.
-
What Is The Aclaris Therapeutics Share Price Today?
Aclaris Therapeutics was last trading at $2.90 per share. This represents the most recent stock quote for Aclaris Therapeutics. Yesterday, Aclaris Therapeutics closed at $2.89 per share.
-
How To Buy Aclaris Therapeutics Stock Online?
In order to purchase Aclaris Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
